Objective. In order to verify the safety and effectiveness of tirofiban combined with statins in the perioperative period of intracranial aneurysms, this study adopts systematic review and meta-analysis, so as to comprehensively understand the situation of intracranial aneurysms in the perioperative period, and tirofiban combined with statins was finally determined as an effective treatment drug. Methods. This study used systematic retrospective analysis and selected 80 patients with intracranial aneurysms treated in our hospital from June 2021 to June 2022 as the research objects. Through conventional drugs and tirofiban combined with statins used in this study, the intracranial levels, the probability of aneurysm rupture, and postoperative complications of the two groups were observed and recorded. Results. The analysis of 80 patients with intracranial aneurysms showed that the influence of intracranial levels in the observation group was better than that in the reference group, the rupture of aneurysms in the observation group was lower than that in the reference group, and the incidence of postoperative complications in the observation group was lower than that in the reference group. Conclusion. Through simulation verification, it is concluded that tirofiban combined with statins is safe and effective in the perioperative application of intracranial aneurysms. This drug can improve vascular recanalization, reduce the incidence of cerebrovascular disease events, and reduce the incidence of rebleeding. Its therapeutic effect is worthy of wide clinical application and promotion.

中文翻译：

---

替罗非班联合他汀类药物治疗颅内动脉瘤围手术期的安全性和有效性：系统评价和荟萃分析

客观。为了验证替罗非班联合他汀类药物在颅内动脉瘤围手术期的安全性和有效性，本研究采用系统回顾和荟萃分析，以全面了解颅内动脉瘤围手术期的情况，以及替罗非班联合他汀类药物在颅内动脉瘤围手术期的应用。他汀类药物最终被确定为有效的治疗药物。方法。本研究采用系统回顾性分析方法，选取2021年6月至2022年6月在我院收治的80例颅内动脉瘤患者作为研究对象。本研究通过常规药物及替罗非班联合他汀类药物,观察并记录两组患者的颅内水平、动脉瘤破裂概率及术后并发症。结果。对80例颅内动脉瘤患者的分析显示，观察组颅内水平的影响优于参考组，观察组动脉瘤破裂率低于参考组，术后发生率也低于参考组。观察组并发症发生率低于参照组。结论。通过模拟验证，得出替罗非班联合他汀类药物在颅内动脉瘤围术期应用中安全有效。该药可改善血管再通，减少脑血管疾病事件的发生，减少再出血的发生。其治疗效果值得临床广泛应用和推广。